Monashee Investment Management LLC Sells 741,135 Shares of Compass Therapeutics, Inc. $CMPX

Monashee Investment Management LLC decreased its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 74.1% during the first quarter, HoldingsChannel reports. The firm owned 258,865 shares of the company’s stock after selling 741,135 shares during the period. Monashee Investment Management LLC’s holdings in Compass Therapeutics were worth $1,369,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CMPX. PNC Financial Services Group Inc. boosted its stake in shares of Compass Therapeutics by 2,572.6% during the first quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock valued at $58,000 after purchasing an additional 10,625 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Compass Therapeutics by 28.7% in the first quarter. Dimensional Fund Advisors LP now owns 439,784 shares of the company’s stock worth $2,324,000 after buying an additional 98,188 shares in the last quarter. Swiss National Bank bought a new position in Compass Therapeutics in the first quarter worth approximately $1,168,000. Independent Financial Group LLC purchased a new stake in Compass Therapeutics during the first quarter worth $121,000. Finally, Y Intercept Hong Kong Ltd boosted its position in Compass Therapeutics by 79.3% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 828,879 shares of the company’s stock valued at $4,385,000 after acquiring an additional 366,713 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

CMPX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Friday, July 17th. D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. HC Wainwright restated a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. Finally, Wall Street Zen downgraded shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $12.25.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX opened at $2.04 on Thursday. The business’s 50-day moving average is $2.11 and its 200 day moving average is $4.14. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88. The firm has a market capitalization of $367.38 million, a P/E ratio of -4.98 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). On average, analysts expect that Compass Therapeutics, Inc. will post -0.42 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.